id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-314546-fbddxbhd	Ko, Meehyun	Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells	2020-08-16		.txt	text/plain	1345	83	47	Although nafamostat mesylate and camostat mesylate were not selected as potent antiviral drug candidates in our earlier study, we compared the antiviral efficacy of these drugs at this time in between Vero and Calu-3 cells following the discovery that TMPRSS2, a host protease necessary for priming viral spike glycoprotein, could be a target for COVID-19 antiviral development. 11 The discrepancy in IC 50 was specifically remarkable with nafamostat mesylate; the IC 50 decreased by approximately 6000 folds when the drug was used in the SARS-CoV-2-infected Calu-3 cells perhaps due to the dominant role of TMPRSS2-dependent viral entry in the Calu-3 human lung epithelial cells. In summary, we compared antiviral efficacy of the potential antiviral drug candidates against SARS-CoV-2 in between Vero and Calu-3 cells and found that nafamostat mesylate is the most potent antiviral drug candidate in vitro. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells	./cache/cord-314546-fbddxbhd.txt	./txt/cord-314546-fbddxbhd.txt